Compugen

Traded on the St. Petersburg Stock Exchange
Compugen is a clinical-stage therapeutic discovery and development company that engages in the research, development, and commercialization of therapeutic and product candidates. Compugen was incorporated in 1993 and is headquartered in Holon, Israel.
Compugen stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Compugen balance sheet

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Compugen cash flows

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Compugen multipliers

Report period2016 2017 2018 2019 2020 2021
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Compugen profitability

Report period2016 2017 2018 2019 2020 2021
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Compugen assets
Compugen cash flows

Compugen dividend policy

The company doesn't provide dividend

Compugen shares

TickerNameTypeNominal valueISINPrice
CGEN:USCompugenCommon share-IL0010852080$1.9
Compugen news
16.05.2022
Compugen's GAAP loss for 3 months of 2022 was $9.71 million, down 2% from $9.905 million in the previous year.
Source: {source} pictogram ir.cgen.com
Pictogram next
24.02.2022
Compugen's GAAP loss for 2021 was $34.203 million, up 15.2% from $29.698 million in the previous year. Revenues tripled to $6 million from $2 million a year earlier.
Source: {source} pictogram ir.cgen.com
Pictogram next
12.11.2021
Compugen's GAAP loss for 9M 2021 was $25.558 million, up 20.9% from $21.135 million in the prior year. Revenues were $6 million. The company did not generate revenues a year earlier.
Source: {source} pictogram ir.cgen.com
Pictogram next
11.11.2021
Bristol Myers Squibb invested $20 million in Compugen. In return, the company received 2,332,815 shares of Compugen stock at $8.57333 per share, a 33% premium over the Nov. 9, 2021 closing price. In addition, as part of the expanded collaboration, a joint committee was formed to strategically manage Compugen's COM701 anti-tumor antibody clinical research pro...
Source: {source} pictogram ir.cgen.com
Pictogram next
All Compugen news
General information
Company nameCompugen
Tags#pharmacy
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business addressBuilding D 26 Harokmim Street Azrieli Center Holon 5885849 Israel
Mailing addressBuilding D 26 Harokmim Street Azrieli Center Holon 5885849 Israel
Websiteir.cgen.com
Information disclosurewww.sec.gov